An orally administered multitarget tyrosine kinase inhibitor, SU11248, is a novel potent inhibitor of thyroid oncogenic RET/papillary thyroid cancer kinases - Kim, DW; Jo, YS; Jung, HS (J Clin Endocrinol Metab, 2006)
et al.